Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACTT2: Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus
KCT0001477Phase 3Completed
- Sponsor
- Altamira Therapeutics
- Start
- Apr 2015
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Keyzilen in peripheral tinnitus, sponsored by Altamira Therapeutics. Started Apr 2015; status: completed.
02
Drugs
Keyzilen
03
Conditions
peripheral tinnitus
Beyond the preview
Go deeper on KCT0001477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001477.